W
WeiDong Ding
Researcher at Pfizer
Publications - 3
Citations - 283
WeiDong Ding is an academic researcher from Pfizer. The author has contributed to research in topics: Bruton's tyrosine kinase & ASK1. The author has an hindex of 3, co-authored 3 publications receiving 187 citations.
Papers
More filters
Journal ArticleDOI
Delineating the role of cooperativity in the design of potent PROTACs for BTK
Adelajda Zorba,Chuong Nguyen,Yingrong Xu,Jeremy T. Starr,Kris A. Borzilleri,James F. Smith,Hongyao Zhu,Kathleen A. Farley,WeiDong Ding,James Schiemer,Xidong Feng,Jeanne S. Chang,Daniel P. Uccello,Jennifer A. Young,Carmen N. Garcia-Irrizary,Lara C. Czabaniuk,Brandon P. Schuff,Robert M. Oliver,Justin I. Montgomery,Matthew Merrill Hayward,Jotham Wadsworth Coe,Jinshan Chen,Mark Niosi,Suman Luthra,Jaymin C. Shah,Ayman El-Kattan,Xiayang Qiu,Graham M. West,Mark C. Noe,Veerabahu Shanmugasundaram,Adam M. Gilbert,Matthew Frank Brown,Matthew F. Calabrese +32 more
TL;DR: It is shown that within a Bruton’s tyrosine kinase/cereblon PROTAC system, potent knockdown correlates with alleviation of steric clashes in the absence of thermodynamic cooperativity, which broadens the scope of PROTAC applications and affects fundamental design criteria across the field.
Journal ArticleDOI
Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitors.
Frank Lovering,Paul Morgan,Christophe Allais,Ann Aulabaugh,Joanne Brodfuehrer,Jeanne Chang,Jotham Wadsworth Coe,WeiDong Ding,Heather V. Dowty,Margaret Fleming,Richard K. Frisbie,Julia A. Guzova,David Hepworth,Jayasankar Jasti,Steve Kortum,Ravi G. Kurumbail,Shashi Mohan,Nikolaos Papaioannou,Strohbach Joseph Walter,Fabien Vincent,Katherine L. Lee,Christoph W. Zapf +21 more
TL;DR: A focused optimization strategy utilizing structure-based design resulted in the identification of ASK1 inhibitors with low nanomolar potency in a cellular assay, high selectivity when tested against kinase and broad pharmacology screening panels, and attractive physicochemical properties.
Journal ArticleDOI
Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors.
Seungil Han,Robert M. Czerwinski,Nicole Caspers,David C. Limburg,WeiDong Ding,Hong Wang,Jeffrey F. Ohren,Francis Rajamohan,Thomas J. McLellan,Ray Unwalla,Chulho Choi,Mihir D. Parikh,Nilufer P. Seth,Jason Edmonds,Christopher Phillips,Subarna Shakya,Xin Li,Vikki Spaulding,Samantha Hughes,Andrew Simon Cook,Colin Robinson,Mathias John Paul,Iva Navratilova,Quintus G. Medley,David R. Anderson,Ravi G. Kurumbail,Ann Aulabaugh +26 more
TL;DR: The discovery of kinase inhibitors that preferentially bind to an allosteric pocket of ITK is described and an optimized lead showed exquisite kinome selectivity and is efficacious in human whole blood and proximal cell-based assays.